Kuur Therapeutics launches to develop and commercialise off-the-shelf CAR-NKT cell therapies

This article was originally published here

IP Group, Baylor College of Medicine and Schroeder Adveq are investing to support two phase 1 studies: GINAKIT 2 (autologous CAR-NKT cells in neuroblastoma) and ANCHOR (allogeneic CAR-NKT

The post Kuur Therapeutics launches to develop and commercialise off-the-shelf CAR-NKT cell therapies appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply